Bridget Obrien, DO
Surgical Oncology · Cedar Park, TXNPI 1841478674
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,625 of the $11,486 with a category attached, or 83.8%. Stryker accounts for 87.0% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2020 at $7,636 and has fallen 95.9% since, to $312 in 2025.
Across 27 payments — averaging $425.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$10K
- Carl Zeiss Meditec, Inc.$986
- Boston Scientific$134
- Johnson & Johnson$88
- Merck$66
- AstraZeneca$57
- plus $163 from 6 others
What the payments were for
- Consulting fees$9,62584%
- Travel & lodging$9869%
- Food & beverage$8758%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 9 | $9,991 |
| Carl Zeiss Meditec, Inc. | 1 | $986 |
| Boston Scientific | 1 | $134 |
| Johnson & Johnson | 4 | $88 |
| Merck | 3 | $66 |
| AstraZeneca | 2 | $57 |
| Astellas Pharma US Inc | 2 | $54 |
| Taiho Oncology, Inc. | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PHOTONBLADE$6,475
- DISPOSABLES - OTHER$3,150
- EIKON LT$2,275
- IORT$986
- SPY-PHI SYSTEM$318
- EMBOLD Fibered$134
How this compares
$11,486 in reported general payments places this provider in the 80th percentile of 191 surgical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 17 | $80 |
| Cephalexin | 11 | $51 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Cedar Park
- Allison DipasqualeDallas$272K
- Merrick RossHouston$216K
- John HardawayShenandoah$164K
- Steven CurleyTyler$162K
- Suhail SharifFort Worth$137K
- Alfredo Santillan GomezSan Antonio$125K
- Kelly HuntHouston$104K
- Adam YoppDallas$96K
- Peter BeitschDallas$62K
- Patricio PolancoDallas$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.